Meta-analysis of sodium glucose transport 2 inhibitors versus other glucose-lowering agents on the progression of diabetic retinopathy and diabetic macular edema.

Diabetes Res Clin PractJul 9, 2026 (epub)
Clinical ResearchEndocrinologyOphthalmology

Rukayat Akande, Stewart G Albert

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on diabetic retinopathy (DR) and diabetic macular edema (DME) progression in a population of 1,785,409 patients. The study found that SGLT2i therapy significantly reduced the relative risk of DR progression (rr = 0.77) and DME progression (rr = 0.75) compared to other glucose-lowering agents.

Key findings

  • SGLT2i therapy reduced the relative risk of DR progression to 0.77 compared to all glucose-lowering agents.
  • The relative risk of DME progression with SGLT2i was 0.75, indicating significant protective effects.
  • The absolute risk difference for DR progression was approximately 4% in cohorts with a 20% baseline rate.
  • SGLT2i showed the most pronounced benefit compared to sulfonylureas.

Why it matters

Understanding the comparative effectiveness of glucose-lowering agents on diabetic retinopathy and macular edema is crucial for optimizing treatment strategies in patients with diabetes, potentially improving long-term ocular outcomes.

Source

PubMed · PMID 42425328

Published in Diabetes Res Clin Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.